DDInter125 DDInter1387
Developed by Schering-Plough after its merger with Organon International, asenapine is a sublingually administered, atypical antipsychotic for treatment of schizophrenia and acute mania associated with bipolar disorder. Asenapine also belongs to the dibenzo-oxepino pyrrole class. It is also for severe post-traumatic stress disorder nightmares in soldiers as an off-label use. FDA approved on August 13, 2009.
Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted. Panobinostat is marketed by Novartis under the brand name Farydak. Panobinostat acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the most potent DAC inhibiting agent available on the market.
Asenapine {u} (Compound) resembles {v} (Compound) Amoxapine
Amoxapine {u} may lead to a major life threatening interaction when taken with {v} Panobinostat
Asenapine {u} (Compound) resembles {v} (Compound) Loxapine
Loxapine {u} (Compound) resembles {v} (Compound) Clozapine
Clozapine {u} may lead to a major life threatening interaction when taken with {v} Panobinostat
Asenapine {u} (Compound) resembles {v} (Compound) Amoxapine
Amoxapine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Panobinostat
Asenapine {u} (Compound) binds {v} (Gene) HRH2
HRH2 {u} (Gene) is bound by {v} (Compound) Olanzapine
Olanzapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Panobinostat
Asenapine {u} (Compound) resembles {v} (Compound) Loxapine
Loxapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chlorpheniramine
Chlorpheniramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Panobinostat
Asenapine {u} (Compound) binds {v} (Gene) HRH1
HRH1 {u} (Gene) is bound by {v} (Compound) Haloperidol
Haloperidol {u} may lead to a major life threatening interaction when taken with {v} Panobinostat
Asenapine {u} (Compound) resembles {v} (Compound) Loxapine
Loxapine {u} (Compound) resembles {v} (Compound) Olanzapine
Olanzapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Panobinostat
Asenapine {u} (Compound) resembles {v} (Compound) Amoxapine
Amoxapine {u} (Compound) resembles {v} (Compound) Olanzapine
Olanzapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Panobinostat
Asenapine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Panobinostat
Asenapine {u} (Compound) resembles {v} (Compound) Loxapine
Loxapine {u} may lead to a major life threatening interaction when taken with {v} Metoclopramide
Metoclopramide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Panobinostat
Asenapine (Compound) resembles Amoxapine (Compound) and Amoxapine may lead to a major life threatening interaction when taken with Panobinostat
Asenapine (Compound) resembles Loxapine (Compound) and Loxapine (Compound) resembles Clozapine (Compound) and Clozapine may lead to a major life threatening interaction when taken with Panobinostat
Asenapine (Compound) resembles Amoxapine (Compound) and Amoxapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Asenapine (Compound) binds HRH2 (Gene) and HRH2 (Gene) is bound by Olanzapine (Compound) and Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Asenapine (Compound) resembles Loxapine (Compound) and Loxapine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Asenapine (Compound) binds HRH1 (Gene) and HRH1 (Gene) is bound by Haloperidol (Compound) and Haloperidol may lead to a major life threatening interaction when taken with Panobinostat
Asenapine (Compound) resembles Loxapine (Compound) and Loxapine (Compound) resembles Olanzapine (Compound) and Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Asenapine (Compound) resembles Amoxapine (Compound) and Amoxapine (Compound) resembles Olanzapine (Compound) and Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Asenapine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Asenapine (Compound) resembles Loxapine (Compound) and Loxapine may lead to a major life threatening interaction when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat